Dr. Camille L. Bedrosian joined Alexion as Chief Medical Officer in May 2008. A medical oncologist and hematologist, she brings more than 25 years of medical practice, research and drug development expertise to this role. At Alexion, she provides leadership for the development of compounds across therapeutic franchises, including expansion of both the PNH franchise as well as additional therapeutic indications for Alexion's marketed product, eculizumab. In addition, she is leading the effort to build the oncology platform initially with the first-in-class anti-CD200 monoclonal antibody.
Dr. Bedrosian has global responsibility for aspects of clinical research, such as clinical operations, clinical data management, medical affairs and pharmacovigilance. In her role, she also interacts extensively with global commercial and business development teams.
Previously, Dr. Bedrosian spent more than five years as the Chief Medical Officer for ARIAD Pharmaceuticals, Inc., which specializes in discovery and development of small molecules to treat cancer by regulating cell signaling. During her tenure with ARIAD, she built and expanded the medical research department from one to nearly 25 members and implemented 13 clinical trials. She led and implemented the strategic development of the company's lead product candidate, deforolimus, successfully through its clinical development from first in human trials to orphan drug designation in both the United States and European Union, to a new dosage form, and to an SPA-approved Phase 3 trial for patients with sarcoma. In 2005, she was recipient of the Symbol of Caring Award from the Sarcoma Foundation of America. She was a pivotal member of the team whose activities resulted in ARIAD's global partnership with Merck & Co., Inc. to further develop and commercialize deforolimus.
Before joining ARIAD, Dr. Bedrosian served from 1997 to 2002 in the Clinical Research and Development Department of Genetics Institute, Inc., which was acquired by Wyeth, and assumed roles of increasing responsibility, ultimately as Senior Director of Oncology/Hematology and Therapeutic Area Director for Hemophilia.
Dr. Bedrosian was an Assistant Professor of Medicine at Duke University Medical Center and member of the Duke Comprehensive Cancer Center, where she also had completed her residency in internal medicine and then fellowship in hematology and medical oncology. During her time at Duke, Dr. Bedrosian worked closely with Professor Wendell Rosse, considered one of the most prominent researchers and clinicians specializing in the rare disease paroxysmal nocturnal hemoglobinuria (PNH). She currently is an Assistant Consulting Professor of Medicine at Duke.
Dr. Bedrosian is the author of numerous research publications, patents, presentations, and abstracts, and is a member of several professional associations, including the American Association for Cancer Research, American Association for the Advancement of Sciences, American Society of Clinical Oncology and American Society of Hematology.
Dr. Bedrosian holds a B.A. degree in Honors Chemistry from Harvard University, an M.D. degree from Harvard Medical School and an M.S. degree in Biophysics from the Massachusetts Institute of Technology.